L&T-TECHNOLOGY-SERVICES
22.11.2017 14:52:13 CET | Business Wire | Press release
L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company announced that it has been positioned in the Leaders Category by independent global research firm, NelsonHall in its latest NEAT evaluation for Internet of Things (IoT) services providers. LTTS is the only global pure-play engineering services to be positioned in the leader’s category.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005331/en/
LTTS has been identified as a leader relative to its peers’ due to its ability to meet future client requirements as well as deliver immediate benefits to IoT Services clients.
Dominique Raviart, IT Services Practice Director, NelsonHall said, “L&T Technology Services has several strengths that make it relevant to industrial IoT. The company has a background in the manufacturing industry. It is actively expanding its IoT portfolio, and has created its own IoT platform, as well as continuing to create IP-based use cases. Also, LTTS has a background in the ER&D industry, which means that it can provide a continuum of services, from product design and engineering to the IoT platform.”
Mr. Bhupendra Bhate, Chief Operating Officer & Whole Time Director, LTTS commented , “Digital Engineering is shaping things of the future. LTTS as the leading pure play engineering services firm is at the forefront of the digital wave and investing its resources and capabilities in transformative areas such as Embedded Systems & Platforms, Human Machine Interface, Big Data Analytics, Integrated Manufacturing & Asset Management and Design Thinking. Acknowledgements such as this from NelsonHall are a testimony that our strategic focus on new age technology is yielding the desired results.”
NelsonHall’s profile of LTTS’ IoT capabilities identified its wide IoT services portfolio which include IoT Platforms and connectivity services, connected devices and ER&D services for Smart Manufacturing.
Some of the key IoT solutions that have been deployed in LTTS’ global customer projects include:
- WAGES , LTTS’ Cloud-based utility usage monitoring solution that is specifically designed to help plant managers collect consumption data from across locations and visualize them as KPIs through a unified dashboard. WAGES refers to Water, Air, Gas Electricity and Steam, the key inputs in a manufacturing process that are tracked & monitored by the solution.
- LTTS has developed a Remote Asset Performance Management Solution for a Construction Major which intends to cover 30 thousand assets across 500 asset types leading to an expected 12% improvement in asset utilization and reduced costs as on-time asset availability improve.
- LTTS’ Personal Protection Equipment Solution includes IoT-enabled Personal Protective gear, an example of advanced wearable technology for industrial usage, that employs a Zigbee interface mechanism whereby alerts and notifications are sent to both personnel’s and their supervisors in case of any breach.
Additionally, NelsonHall identified key strengths of LTTS which include:
- Background in smart manufacturing, an area where IoT demand stems from
- Credibility in elements of IoT services, namely embedded systems, mechanical engineering, connectivity and telecom services
- Financial capabilities to invest in IoT offerings
- Development of proprietary IP
NelsonHall noted that LTTS is investing in developing IP use cases and creating Intellectual Assets that are reusable like the smart building framework i-BEMS that enables ‘Net-Zero,’ energy generation management in buildings.
About L&T Technology Services Limited:
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 52 Fortune 500 companies and 48 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have around 11,000 employees spread across 15 global delivery centers, 28 global sales offices and 38 innovation labs in India as of September 30, 2017.
For additional information about L&T Technology Services log on to www.LntTechservices.com .
About NelsonHall:
NelsonHall is the leading global analyst firm dedicated to helping organizations understand the ‘art of the possible’ in next generation IT and business services. With analysts in the U.S., U.K., and Continental Europe, NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors that helps them make fast and highly informed sourcing decisions. And for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall’s research is rigorous and all-original, and widely respected for the quality, depth and insight of its analysis.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171122005331/en/
Contact:
L&T Technology Services Limited
Aniruddha Basu, +91-80-67675173
Aniruddha.Basu@LntTechservices.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom